Total amount raised
$136.2 Millions
Latest funding date
10/01/2024
Location
Vizgen has successfully raised capital through multiple funding rounds, with the latest being a Series D round. The company is backed by eight investors, including ARCH Venture Partners and Northpond Ventures.
Keep reading to explore the intricacies of Vizgen's fundraising journey and the investors backing this innovative biotech platform.
What Is Vizgen?
Vizgen, founded on March 7, 2019, is a biotech company based in Cambridge, Massachusetts. The company was established by David R. Walt, George Emanuel, and Jiang He.
Specializing in single-cell spatial genomics, Vizgen employs its patented MERFISH technology to develop advanced tools for genome-scale nucleic acid imaging. The company has a workforce of 101-250 employees and offers products like the MERSCOPE Platform and MERSCOPE Ultra.
How Much Funding Has Vizgen Raised?
- Series A
- Amount Raised: $14M
- Date: January 2020
- Lead Investors: ARCH Venture Partners, Northpond Ventures
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To develop and commercialize the MERSCOPE Platform.
- Series B
- Amount Raised: $37M
- Date: April 2021
- Lead Investors: Northpond Ventures, Novalis LifeSciences
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To expand the capabilities of the MERSCOPE Platform and accelerate product development.
- Series C
- Amount Raised: $85.2M
- Date: June 2022
- Lead Investors: ARCH Venture Partners, Blue Water Life Science Advisors
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support the continued growth and development of the MERSCOPE Platform.
- Series D
- Amount Raised: Not publicly disclosed
- Date: October 2024
- Lead Investors: Not publicly disclosed
- Valuation at Round: Not publicly disclosed
- Motivation Behind the Round: To support long-term success and defense against anti-competitive legal actions.
Total Amount Raised: $136.2M
Current Valuation: Not publicly disclosed
Key Investors
- ARCH Venture Partners
- Details: ARCH Venture Partners is a venture capital firm that invests in advanced technology companies. They have a strong focus on early-stage investments.
- Investment Focus Areas: Advanced technology, life sciences, biotechnology
- Notable Investments: Not publicly disclosed
- Northpond Ventures
- Details: Northpond Ventures is a venture capital firm specializing in life sciences and technology. They aim to support companies that are at the forefront of scientific innovation.
- Investment Focus Areas: Life sciences, technology, healthcare
- Notable Investments: Not publicly disclosed
- Blue Water Life Science Advisors
- Details: Blue Water Life Science Advisors is a venture capital firm focused on life sciences. They led the Series C funding round for Vizgen.
- Investment Focus Areas: Life sciences
- Notable Investments: Not publicly disclosed
- Novalis LifeSciences
- Details: Novalis LifeSciences is a life sciences investment and advisory firm. They participated in the Series C funding round for Vizgen.
- Investment Focus Areas: Life sciences
- Notable Investments: Not publicly disclosed
- Sofina
- Details: Sofina is an investment company with a diversified portfolio. They participated in the Series C funding round for Vizgen.
- Investment Focus Areas: Diversified investments across various sectors
- Notable Investments: Not publicly disclosed
What's Next for Vizgen?
Vizgen stands at the cusp of significant growth, driven by the expansion of its MERSCOPE Platform. The high detection efficiency and resolution of their MERFISH technology present vast opportunities in the U.S. and potentially global markets. This positions Vizgen to attract more research and commercial clients, further solidifying its presence in the single-cell spatial genomics field.
Future fundraising efforts could see Vizgen exploring additional venture capital rounds or strategic partnerships, leveraging the strong investor confidence demonstrated in their Series C funding. However, the company may face challenges such as competition from other genomic technology developers and the need to continuously innovate to maintain their technological edge.
Use Clay to Get Funding Data
Sales professionals, take your strategy to the next level by leveraging Clay’s platform to access comprehensive fundraising data on companies like Vizgen and gather other critical business insights.
Sign up for free to start exploring the wealth of information available at your fingertips.
